Patent · US Active

PEG-ACS/M-siRNA nanocomposite, application thereof, and method for reducing histamine content during fishmeal storage

US10982015B2 · kind B2 · utility

0Cited by
0References
20Claims
0Family size

Assignees

Inventors

Key dates

Filing dateSep 18, 2018
Grant dateApr 20, 2021
Priority date
Expiry dateNov 30, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Y401/01022
  • WIPO fieldMacromolecular chemistry, polymers
  • WIPO sectorChemistry

Abstract

The present invention provides a PEG-ACS/M-siRNA nanocomposite application, and method for reducing the histamine content during fishmeal storage thereof. A small interfering ribonucleic acid (siRNA) is designed and prepared according to a histidine decarboxylase gene of Morganella morganii (Morganella morganii subsp. morganii KT), and the histidine decarboxylase gene has a sequence of SEQ ID No: 1. A PEG-ACS/M-siRNA nanocomposite is prepared by using a PEGylated arginine-modified chitosan as a carrier. A PEG-ACS/M-siRNA nanocomposite is added to fishmeal in a certain ratio. The method for reducing the histamine content during fishmeal storage has a significant inhibitory effect on the histamine content during fishmeal storage, and can reduce the histamine content in fishmeal by 49%-53%, which has great significance for the control of biogenic amines in fishmeal in the feed industry.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.